Biosimilars and Biologics in Cancer Treatment : An Era in Therapeutic Strategies

個数：

予約

Biosimilars and Biologics in Cancer Treatment : An Era in Therapeutic Strategies

Anitha, Kuttiappan (EDT)/ Bhatt, Shvetank (EDT)/ Bandaru, Nagaraju (EDT)

ウェブストア価格 ¥37,945（本体¥34,496）
Academic Press Inc（2026/04発売）
外貨定価 US$ 175.00
ポイント 344pt

現在予約受付中です。出版後の入荷・発送となります。
（重要：表示されている発売日は予定となり、発売が延期、中止、生産限定品で商品確保ができないなどの理由により、ご注文をお取消しさせていただく場合がございます。予めご了承ください。）

●3Dセキュア導入とクレジットカードによるお支払いについて

【入荷遅延について】
世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。

◆画像の表紙や帯等は実物とは異なる場合があります。

◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
また、洋書販売価格は、ご注文確定時点での日本円価格となります。
ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。

製本 Paperback:紙装版/ペーパーバック版／ページ数 440 p.
言語 ENG
商品コード 9780443438240

Full Description

Biosimilars and Biologics in Cancer Therapy: An Era in Therapeutic Strategies offers an in-depth exploration of the evolving role of biosimilars and biologics in cancer treatment. The book presents a clear overview of the challenges and opportunities these therapies bring, backed by current evidence and a thorough discussion of regulatory and economic factors. It serves as a comprehensive educational resource designed to bridge the gap between cutting-edge research and everyday clinical practice, providing readers with a solid foundation in the fundamental principles, historical context, and mechanisms of action behind biologics and biosimilars.

Readers will also discover emerging strategies such as combination therapies and personalized medicine, ensuring the content is relevant for researchers, clinicians, and other healthcare professionals. International expert contributors share the latest advancements, offering practical guidance for integrating biosimilars and biologics into cancer care and inspiring future oncology research.

1. Introduction to Biosimilars and Biologics
2. Opportunities and Challenges in the Biosimilars and Biologics
3. Impact of Biosimilars and Biologics in Cancer Treatment
4. Clinical Applications of Biologics and Biosimilars in Oncology
5. Biosimilars and Biologics in Breast Cancer
6. Biosimilars and Biologics in Gastric and Colorectal Cancer
7. Biosimilars and Biologics in Cervical Cancer
8. Biosimilars and Biologics in Lung Cancer
9. Biosimilars and Biologics in Hepatocellular Carcinoma
10. Biosimilars and Biologics in Brain Tumor
11. Biosimilars and Biologics in Pancreatic Cancer
12. Biosimilars and Biologics in Prostate Cancer
13. Biosimilars and Biologics in Ovarian Cancer
14. Biosimilars and Biologics in Bone Cancer
15. Biosimilars and Biologics in Endometrial/Uterine Cancer
16. Biosimilars and Biologics in Urothelial Carcinoma
17. Biosimilars and Biologics in Melanoma
18. Biologics and Biosimilars from the Bench to the Bedside in Oncology
19. Recent Evidence of Biologics and Biosimilars and its Perspectives on Clinical Advances and Emerging Approaches
20. Marching of Biologics and Biosimilars in Artificial Intelligence and Machine Learning as Tools to Detect Various Cancer